Prescreening of Natural Products in Drug Discovery Using Recombinant Bioluminescent Bacteria

Eui Jong Kim, Ho Bin Seo, Man Bock Gu

Research output: Contribution to journalArticle

Abstract

Strains of recombinant bioluminescent bacteria (RBB) which respond to toxic environments using various stress promoters are practical means of assessing toxicity. In previous research, RBB has proven useful for highthroughput screening in the drug development process. The goal of this research is to demonstrate that RBB can also be used for the toxicity screening of natural products. The RBB strains used were DPD2511, BBTSbmC, TV1061, and GC2, which were selected to respond to oxidative stress, DNA damage, protein damage, and cellular toxicity, respectively. The test drugs (paclitaxel, etoposide, and pentostatin) were carefully selected because these drugs needed to be natural products or their derivatives whose cellular toxicity had previously been reported from human cell line assays. After treating the RBB strains with various doses of the chosen drugs, their bioluminescent signals were measured over time. The effectiveness of the RBB method was proven by comparing its results to existing toxicity data for the selected drugs. In addition, a similar test using podophyllotoxin, a precursor of etoposide, and a derivative of podophyllotoxin, teniposide, was conducted to prove that the RBB method is suitable for a comparative analysis of toxicity among chemicals with similar molecular structures. As a detection method, RBB bacteria provide a much easier and more rapid culturing process compared to conventional human cell line assays. Because the implementation of the RBB method in the drug discovery process would enable efficient prescreening, a significant reduction in time, effort, and development costs are expected.

Original languageEnglish
Pages (from-to)264-271
Number of pages8
JournalBiotechnology and Bioprocess Engineering
Volume24
Issue number1
DOIs
Publication statusPublished - 2019 Feb 1

Fingerprint

Drug Discovery
Biological Products
Bacteria
Toxicity
Podophyllotoxin
Pharmaceutical Preparations
Etoposide
Assays
Screening
Cells
Pentostatin
Teniposide
Derivatives
Cell Line
Preclinical Drug Evaluations
Oxidative stress
Poisons
Paclitaxel
Molecular Structure
Research

Keywords

  • drug discovery
  • natural products
  • prescreening
  • recombinant bioluminescent bacteria (RBB)

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Biomedical Engineering

Cite this

Prescreening of Natural Products in Drug Discovery Using Recombinant Bioluminescent Bacteria. / Kim, Eui Jong; Seo, Ho Bin; Gu, Man Bock.

In: Biotechnology and Bioprocess Engineering, Vol. 24, No. 1, 01.02.2019, p. 264-271.

Research output: Contribution to journalArticle

@article{d2c48e8500a74d4898f8929490755acc,
title = "Prescreening of Natural Products in Drug Discovery Using Recombinant Bioluminescent Bacteria",
abstract = "Strains of recombinant bioluminescent bacteria (RBB) which respond to toxic environments using various stress promoters are practical means of assessing toxicity. In previous research, RBB has proven useful for highthroughput screening in the drug development process. The goal of this research is to demonstrate that RBB can also be used for the toxicity screening of natural products. The RBB strains used were DPD2511, BBTSbmC, TV1061, and GC2, which were selected to respond to oxidative stress, DNA damage, protein damage, and cellular toxicity, respectively. The test drugs (paclitaxel, etoposide, and pentostatin) were carefully selected because these drugs needed to be natural products or their derivatives whose cellular toxicity had previously been reported from human cell line assays. After treating the RBB strains with various doses of the chosen drugs, their bioluminescent signals were measured over time. The effectiveness of the RBB method was proven by comparing its results to existing toxicity data for the selected drugs. In addition, a similar test using podophyllotoxin, a precursor of etoposide, and a derivative of podophyllotoxin, teniposide, was conducted to prove that the RBB method is suitable for a comparative analysis of toxicity among chemicals with similar molecular structures. As a detection method, RBB bacteria provide a much easier and more rapid culturing process compared to conventional human cell line assays. Because the implementation of the RBB method in the drug discovery process would enable efficient prescreening, a significant reduction in time, effort, and development costs are expected.",
keywords = "drug discovery, natural products, prescreening, recombinant bioluminescent bacteria (RBB)",
author = "Kim, {Eui Jong} and Seo, {Ho Bin} and Gu, {Man Bock}",
year = "2019",
month = "2",
day = "1",
doi = "10.1007/s12257-018-0384-4",
language = "English",
volume = "24",
pages = "264--271",
journal = "Biotechnology and Bioprocess Engineering",
issn = "1226-8372",
publisher = "Korean Society for Biotechnology and Bioengineering",
number = "1",

}

TY - JOUR

T1 - Prescreening of Natural Products in Drug Discovery Using Recombinant Bioluminescent Bacteria

AU - Kim, Eui Jong

AU - Seo, Ho Bin

AU - Gu, Man Bock

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Strains of recombinant bioluminescent bacteria (RBB) which respond to toxic environments using various stress promoters are practical means of assessing toxicity. In previous research, RBB has proven useful for highthroughput screening in the drug development process. The goal of this research is to demonstrate that RBB can also be used for the toxicity screening of natural products. The RBB strains used were DPD2511, BBTSbmC, TV1061, and GC2, which were selected to respond to oxidative stress, DNA damage, protein damage, and cellular toxicity, respectively. The test drugs (paclitaxel, etoposide, and pentostatin) were carefully selected because these drugs needed to be natural products or their derivatives whose cellular toxicity had previously been reported from human cell line assays. After treating the RBB strains with various doses of the chosen drugs, their bioluminescent signals were measured over time. The effectiveness of the RBB method was proven by comparing its results to existing toxicity data for the selected drugs. In addition, a similar test using podophyllotoxin, a precursor of etoposide, and a derivative of podophyllotoxin, teniposide, was conducted to prove that the RBB method is suitable for a comparative analysis of toxicity among chemicals with similar molecular structures. As a detection method, RBB bacteria provide a much easier and more rapid culturing process compared to conventional human cell line assays. Because the implementation of the RBB method in the drug discovery process would enable efficient prescreening, a significant reduction in time, effort, and development costs are expected.

AB - Strains of recombinant bioluminescent bacteria (RBB) which respond to toxic environments using various stress promoters are practical means of assessing toxicity. In previous research, RBB has proven useful for highthroughput screening in the drug development process. The goal of this research is to demonstrate that RBB can also be used for the toxicity screening of natural products. The RBB strains used were DPD2511, BBTSbmC, TV1061, and GC2, which were selected to respond to oxidative stress, DNA damage, protein damage, and cellular toxicity, respectively. The test drugs (paclitaxel, etoposide, and pentostatin) were carefully selected because these drugs needed to be natural products or their derivatives whose cellular toxicity had previously been reported from human cell line assays. After treating the RBB strains with various doses of the chosen drugs, their bioluminescent signals were measured over time. The effectiveness of the RBB method was proven by comparing its results to existing toxicity data for the selected drugs. In addition, a similar test using podophyllotoxin, a precursor of etoposide, and a derivative of podophyllotoxin, teniposide, was conducted to prove that the RBB method is suitable for a comparative analysis of toxicity among chemicals with similar molecular structures. As a detection method, RBB bacteria provide a much easier and more rapid culturing process compared to conventional human cell line assays. Because the implementation of the RBB method in the drug discovery process would enable efficient prescreening, a significant reduction in time, effort, and development costs are expected.

KW - drug discovery

KW - natural products

KW - prescreening

KW - recombinant bioluminescent bacteria (RBB)

UR - http://www.scopus.com/inward/record.url?scp=85062940168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062940168&partnerID=8YFLogxK

U2 - 10.1007/s12257-018-0384-4

DO - 10.1007/s12257-018-0384-4

M3 - Article

AN - SCOPUS:85062940168

VL - 24

SP - 264

EP - 271

JO - Biotechnology and Bioprocess Engineering

JF - Biotechnology and Bioprocess Engineering

SN - 1226-8372

IS - 1

ER -